Abstract: A battery diagnosis apparatus for diagnosis of a cell group including a plurality of battery cells connected in series, includes a voltage sensing circuit configured to periodically generate a voltage signal indicating a cell voltage of each battery cell, and a control circuit configured to generate time series data indicating a change in cell voltage of each battery cell over time based on the voltage signal. The control circuit is configured to (i) determine a first average cell voltage and a second average cell voltage of each battery cell based on the time series data, wherein the first average cell voltage is a short term moving average, and the second average cell voltage is a long term moving average, and (ii) detect an abnormal voltage of each battery cell based on a difference between the first average cell voltage and the second average cell voltage.

Abstract: The present invention relates to a pharmaceutical composition comprising an immunoglobulin Fc region and an IL-7 fusion protein. Specifically, when a fusion protein comprising the immunoglobulin Fc region and IL-7 is administered to an affected area, a strong immune response is induced in the body and thus allows human papillomavirus-caused diseases to be prevented or treated.

Abstract: A battery diagnosis apparatus for diagnosis of a cell group including a plurality of battery cells connected in series, includes a voltage sensing circuit configured to periodically generate a voltage signal indicating a cell voltage of each battery cell, and a control circuit configured to generate time series data indicating a change in cell voltage of each battery cell over time based on the voltage signal. The control circuit is configured to (i) determine a first average cell voltage and a second average cell voltage of each battery cell based on the time series data, wherein the first average cell voltage is a short term moving average, and the second average cell voltage is a long term moving average, and (ii) detect an abnormal voltage of each battery cell based on a difference between the first average cell voltage and the second average cell voltage.

Abstract: A battery apparatus estimates a surface SOC representing a potential at an electrode surface of the battery, and predicts an output of the battery during a requested time based on the first surface SOC, a cut-off voltage, and the requested time.

Abstract: The present invention relates to a fusion protein including PD-L1 protein and a modified immunoglobulin Fc region and use thereof, and since the fusion protein has significantly higher purity and production yield compared to the existing fusion protein, has a high binding affinity to PD-1, reduces the proliferation of activated T cells, inhibits the generation of cytokines generated by activated T cells, and has an effect of inhibiting the infiltration of T cells or macrophages into tissues, it can be effectively used in the treatment of immune diseases.

Abstract: A single channel-based multi-functional light emitting diode lamp driving system includes: first and second light source groups distinguished for each lamp function thereof; a single LED lamp driving module adjusting an input voltage to a voltage required for each lamp function and to apply it to the first and second light source groups; a switching module controlling on or off of the first and second light source groups; and a control module controlling light amounts of the first and second light source groups by performing time-division control on an on or off time of the switching module in conjunction with the LED lamp driving module, wherein the control module is configured to perform time division turn-on control on the first and second light source groups by controlling at least one of a current value applied to the first and second light source groups or a duty ratio thereof in a high-beam passing mode.

Abstract: The present invention relates to a pharmaceutical composition comprising an interleukin-7 fusion protein to which an immunoglobulin Fc region has been fused for preventing or treating diseases caused by influenza virus A. The fusion protein comprising the immunoglobulin Fc region and IL-7 according to the present invention protects the body from infection due to influenza virus A and thus can treat diseases which can be caused by the virus.

Abstract: A semiconductor device includes a plurality of bit line structures formed to be spaced apart from each other over a semiconductor substrate, a first spacer formed on both sidewalls of each of the bit line structures, a lower plug formed between the bit line structures and in contact with the semiconductor substrate, an upper plug positioned over the lower plug and having a greater line width than the lower plug, a middle plug positioned between the lower plug and the upper plug and having a smaller line width than a line width of the lower plug, and a second spacer positioned between the middle plug and the first spacer, wherein the second spacer is thicker than the first spacer.

Abstract: A recombinant lentiviral vector containing a gene encoding a TRAIL protein and a CD protein; and a cell that is transfected with the lentivirus produced by using the vector. A host cell transfected with the recombinant lentivirus maintains a high cell proliferation rate and overexpresses a TRAIL protein and a CD protein. Thus, a mesenchymal stem cell transfected with the lentivirus may be usefully employed as a cell therapeutic agent.

Abstract: A recombinant lentiviral vector includes a gene encoding a hepatocyte growth factor (HGF) protein. And a cell that is transfected with the lentivirus produced by using the vector is provided. The recombinant lentivirus includes a gene encoding a HGF protein, and a host cell transfected with the lentivirus maintains a high cell proliferation rate. Thus, a mesenchymal stem cell expressing HGF by being transfected with the lentivirus may be usefully employed as a cell therapeutic agent.

Abstract: The present invention relates to a method for treating anemia using a long-acting EPO formulation, and more specifically, a method for treating patients with anemia by confirmation of safe, long-acting, and optimal effective dosage and usage in administering a fusion polypeptide which comprises an EPO and an immunoglobulin hybrid Fc to patients with anemia. The method of administering the fusion polypeptide employs an appropriate dosage and usage which not only shows an excellent long-acting property compared to the existing EPO products but also minimizes cardiovascular side effects that may occur due to a rapid increase in hemoglobin level, which is an effect of anemia treatment.

Abstract: A composition containing, as active ingredients, probiotics and a polypeptide with a binding ability to IgE is disclosed. In particular, a synergistic effect of remarkably decreasing food allergy was identified at the time of combined administration of probiotics and a recombinant protein containing an extracellular domain of an alpha subunit of an IgE Fc receptor. Therefore, it is expected that the composition is highly industrially applicable due to being able to exhibit a remarkable therapeutic effect on an IgE-mediated allergic disease as compared with conventional pharmaceutical compositions.

Abstract: The present invention provides a genetically modified NK cell line prepared by transducing host NK cell line with a gene construction encoding a cancer antigen-specific chimeric antigen receptor (CAR) comprising a FLT3-specific monoclonal antibody or a functional fragment thereof, a transmembrane domain, and a CD3? domain of a T-cell receptor for more efficient immunotherapy of acute myeloid leukemia, and use thereof, for more efficient immunotherapy of acute myeloid leukemia.

Abstract: A method for increasing a lymphocyte count in a subject in need thereof including administering to the subject (i) a modified interleukin-7 of the following formula (I): A?IL-7 wherein A is an oligopeptide consisting of 1 to 10 amino acid residues, and the IL-7 is a polypeptide which is capable of binding to IL-7 receptor; or (ii) an interleukin-7 fusion protein comprising (a) the modified interleukin-7, (b) a second domain containing an oligopeptide having 1 to 10 amino acid residues consisting of methionine, glycine, or a combination thereof; and (c) a third domain which prolongs the half-life of the interleukin-7 fusion protein.

Abstract: Provided is an apparatus and method for diagnosing a communication fault. The apparatus includes a first slave module, a second slave module and a master module. The first slave module receives a synchronization signal through the first communication line and a first output signal through the second communication line, and transmits an input signal through the third communication line. The second slave module receives synchronization signal through the first communication line, and transmits a comparison signal to the master module through the third communication line when the second slave module receives a second output signal through the second communication line. The master module transmits the synchronization signal, the first output signal and the second output signal, and diagnose a communication fault by comparing a value of the comparison signal with a predetermined reference value or a value of the input signal.

Abstract: A rebar movement-prevention-type one-touch coupler is configured to allow rebars to be fixed without a movement of the rebars after performing a one-touch insertion. A fixation of the rebars is completed by performing an additional tightening operation to housing units into which the rebars are inserted. The coupler increases both the fixation stability of the rebar and the safety of a structure employing the rebar.

Abstract: A system for driving a multi-functional light emitting diode (LED) lamp includes a first light source group and a second light source group classified depending on lamp functions, a single LED lamp driving device to regulate an input voltage to a voltage necessary for each lamp function and to apply the voltage to the first light source group and the second light source group, a switching device to control an On/Off state of the first light source group and the second light source group, and a control device to time-division control a time to turn on/off the switching device by internetworking with the LED lamp driving device and to control a light quantity of the first light source group and the second light source group.

Abstract: The present invention relates to a pharmaceutical composition comprising an interleukin-7 fusion protein to which an immunoglobulin Fc region has been fused for preventing or treating diseases caused by influenza virus A. The fusion protein comprising the immunoglobulin Fc region and IL-7 according to the present invention protects the body from infection due to influenza virus A and thus can treat diseases which can be caused by the virus.

Abstract: The present disclosure relates to a method for estimating a state of charge (SOC) of a battery and a battery management system applying the same. A method for estimating a SOC of a battery in a method for estimating a SOC of a battery module assembly including battery modules respectively including a plurality of battery cells includes: receiving a battery current from a current sensor; comparing the battery current and a threshold current, and selecting a method for estimating a first SOC or a method for estimating a second SOC according to a comparison result; estimating a SOC of the cells according to the selected method for estimating a state of charge; and estimating the SOC of the battery module assembly by combining the estimated SOC of the battery cells.

Abstract: Embodiments of the present disclosure relate to a memory system, a memory controller, and a method for operating a memory system. According to embodiments of the present disclosure, a memory system may configure first peak power management information for controlling the plurality of memory dies, may determine, when an error occurs while controlling a plurality of memory dies, new peak power management information corresponding to operation information and environment information at the time at which the error occurs, respectively, and may change from the first peak power management information to the second peak power management information according to subsequent operation information and environment information. Accordingly, the memory system is capable of minimizing the possibility of occurrence of errors in a read, write, or erase operation and increasing the stability of an operation for transmitting and receiving commands or data to and from the host.